Summary

Liraglutide, an analogue for human glucagon-like peptide 1, is approved for patients with type 2 diabetes mellitus and is associated with HbA1C reductions of 1.0% to 1.5% and moderate weight loss. Diabetes is associated with a 2-fold increased risk of cardiovascular (CV) events. The ongoing Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation trial [LEADER; NCT01179048] is evaluating the CV safety of liraglutide, in accordance with requirements of the United States Food and Drug Administration.